CN115569165B - 中药组合物在制备治疗细菌性前列腺炎的药物中的应用 - Google Patents
中药组合物在制备治疗细菌性前列腺炎的药物中的应用 Download PDFInfo
- Publication number
- CN115569165B CN115569165B CN202211275190.9A CN202211275190A CN115569165B CN 115569165 B CN115569165 B CN 115569165B CN 202211275190 A CN202211275190 A CN 202211275190A CN 115569165 B CN115569165 B CN 115569165B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- traditional chinese
- chinese medicine
- bacterial prostatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 206010069918 Bacterial prostatitis Diseases 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 8
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 37
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 37
- 229960003321 baicalin Drugs 0.000 claims abstract description 37
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000004380 Cholic acid Substances 0.000 claims abstract description 36
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 36
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 36
- 229960002471 cholic acid Drugs 0.000 claims abstract description 36
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229930186147 Cephalosporin Natural products 0.000 claims abstract description 27
- 229940124587 cephalosporin Drugs 0.000 claims abstract description 27
- 150000001780 cephalosporins Chemical class 0.000 claims abstract description 27
- 201000007094 prostatitis Diseases 0.000 claims abstract description 24
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 20
- 244000227573 Desmodium styracifolium Species 0.000 claims abstract description 20
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims abstract description 20
- 240000008537 Burchellia bubalina Species 0.000 claims abstract description 19
- 235000004415 Burchellia bubalina Nutrition 0.000 claims abstract description 19
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000010231 banlangen Substances 0.000 claims abstract description 18
- 239000008187 granular material Substances 0.000 claims description 37
- 241000157835 Gardenia Species 0.000 claims description 18
- 241000191967 Staphylococcus aureus Species 0.000 claims description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 5
- 229960003719 cefdinir Drugs 0.000 claims description 5
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 5
- 229960002129 cefixime Drugs 0.000 claims description 5
- 229960002588 cefradine Drugs 0.000 claims description 5
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 5
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 241000334160 Isatis Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 241000522190 Desmodium Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 25
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 4
- 239000012747 synergistic agent Substances 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 51
- 239000000284 extract Substances 0.000 description 27
- 238000010438 heat treatment Methods 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000008923 Qingkailing Substances 0.000 description 23
- 241000700159 Rattus Species 0.000 description 21
- 238000002156 mixing Methods 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- 238000001914 filtration Methods 0.000 description 19
- 238000005303 weighing Methods 0.000 description 19
- 210000002307 prostate Anatomy 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000002270 dispersing agent Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000001035 drying Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000686 essence Substances 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241000217407 Margaritifera Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010004542 Bezoar Diseases 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 4
- 229910001863 barium hydroxide Inorganic materials 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 208000013507 chronic prostatitis Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 244000111489 Gardenia augusta Species 0.000 description 2
- 235000018958 Gardenia augusta Nutrition 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 208000026455 prostate symptom Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了中药组合物在制备治疗细菌性前列腺炎的药物中的应用。所述中药组合物由胆酸、猪去氧胆酸、水牛角、板蓝根、金银花、栀子、黄芩苷和珍珠母组成。本发明的中药组合物对细菌性前列腺炎具有明显的改善效果，减少病原感染，缓解炎症反应。而且研究数据显示，所述中药组合物能够明显提升头孢类药物对细菌性前列腺炎的治疗作用，因此可以作为增效剂与该药物联用，用于细菌性前列腺炎的治疗。所述中药组合物还可加入广金钱草构成新方，对细菌性前列腺炎有更好的疗效，且同样可作为增效剂与头孢类药物联用，无毒安全，见效快，对临床前列腺炎的治疗具有重要的价值。
Description
技术领域
本发明涉及中药领域，具体地，涉及中药组合物在制备治疗细菌性前列腺炎的药物中的应用。
背景技术
前列腺炎是常见的男科疾病。美国国立卫生研究所(NIH)将前列腺炎分为四型，即Ⅰ型急性细菌性前列腺炎，Ⅱ型慢性细菌性前列腺炎，Ⅲ型是慢性非细菌性前列腺炎，Ⅳ型是盆底疼痛综合征。其中，Ⅰ型和Ⅱ型前列腺炎有细菌感染，而Ⅲ型和Ⅳ型前列腺炎没有细菌感染，治疗难度大。
中医是世界上最古老的医疗体系之一，已有数千年的历史，其中最享有盛名的为中草药治疗。中医理论中，常用“经灼”、“精浊”表示包括慢性前列腺炎在内的前列腺疾病，即阴虚火旺、内外湿热、肝郁气滞、性交过盛导致的排尿困难等症状。在中医理论指导下，可用促进血液循环和下肢去湿热的方法进行治疗，例如排尿通淋、清热利湿、化瘀活血等。
中医上按照病因病机将前列腺炎分为急慢性来分别论述，急性者多由于饮食偏嗜，好饮酒且食肥甘，酿湿蕴热；或因外感湿热时邪，聚于下焦而得。慢性者多由相火不安于位，或所愿难就，或强忍精不泄，肾火郁而不散，离位之精败而化生白浊；或房事不节，精室空虚。湿热邪气自精道内侵而入，湿热壅而滞，气血瘀阻所成。病久伤阴，肾阴大耗，则现阴虚火旺之证候；亦或有素来身体偏于阳虚者，久病，则命门之火衰微矣，可见肾阳不足之证候。
现有治疗前列腺炎的药物，如头孢等消炎类药物，能够消炎抑菌，主要用于细菌性前列腺炎，以及盐酸坦索罗辛等改善前列腺症状的药物，能够缓解尿频、尿急、排尿不畅等。但目前临床上治疗效果仍不甚理想，如何提高前列腺炎治疗效果一直是众多男科医生们所关注的临床问题。
发明内容
为了克服现有技术中存在的前列腺炎治疗难度大的问题，并增补前列腺炎治疗药物选择，本发明的目的是提供中药组合物在制备治疗细菌性前列腺炎的药物的应用，及其与头孢类药物联用，用于临床前列腺炎的治疗，无毒安全，见效快，对临床前列腺炎的治疗具有重要的价值。
为了实现上述目的，本发明是通过以下方案予以实现的：
一种中药组合物在制备治疗细菌性前列腺炎的药物中的应用，所述中药组合物包含胆酸、猪去氧胆酸、水牛角、板蓝根、金银花、栀子、黄芩苷和/或珍珠母。
一种联用组合药物在制备治疗细菌性前列腺炎的药物中的应用也应在本发明的保护范围之内，所述联用组合药物含有中药组合物和头孢类药物，所述中药组合物包含胆酸、猪去氧胆酸、水牛角、板蓝根、金银花、栀子、黄芩苷和/或珍珠母。
优选地，所述中药组合物包含胆酸3～4重量份、猪去氧胆酸2～4重量份、水牛角22～28重量份、板蓝根180～220重量份、金银花55～65重量份、栀子22～28重量份、黄芩苷4～6重量份和/或珍珠母45～55重量份。
更优选地，所述中药组合物包含胆酸3.25重量份、猪去氧胆酸3.75重量份、水牛角25重量份、板蓝根200重量份、金银花60重量份、栀子25重量份、黄芩苷5重量份和/或珍珠母50重量份。
优选地，所述中药组合物还包含广金钱草。
更优选地，所述中药组合物还包含广金钱草15～30重量份。
进一步地，所述中药组合物还包含广金钱草18重量份。
优选地，所述细菌性前列腺炎为急性细菌性前列腺炎和/或慢性细菌性前列腺炎。
优选地，所述细菌性前列腺炎的病原菌含有大肠杆菌、表皮葡萄球菌、金黄色葡萄球菌和/或铜绿假单胞菌中的一种或几种。
更优选地，所述细菌性前列腺炎的病原菌为大肠杆菌、表皮葡萄球菌、金黄色葡萄球菌和/或铜绿假单胞菌中的一种或几种。
一种治疗细菌性前列腺炎的药物，包含胆酸、猪去氧胆酸、水牛角、板蓝根、金银花、栀子、黄芩苷、珍珠母和广金钱草。
优选地，所述药物包含胆酸3～4重量份、猪去氧胆酸2～4重量份、水牛角22～28重量份、板蓝根180～220重量份、金银花55～65重量份、栀子22～28重量份、黄芩苷4～6重量份、珍珠母45～55重量份和广金钱草15～30重量份。
更优选地，所述药物包含胆酸3.25重量份、猪去氧胆酸3.75重量份、水牛角25重量份、板蓝根200重量份、金银花60重量份、栀子25重量份、黄芩苷5重量份、珍珠母50重量份和广金钱草18重量份。
进一步地，所述药物还包含头孢类药物。
更进一步地，所述头孢类药物为头孢克肟、头孢拉定和/或头孢地尼中的一种或几种。
更进一步地，所述头孢类药物为头孢克肟颗粒、头孢拉定胶囊和头孢地尼颗粒中的一种或几种。
中医认为慢性前列腺炎与肝、脾、肾、膀胱相关，初起多为湿、热、瘀、滞，后期出现气虚、阴亏、阳衰等，病久表现为虚实夹杂。因过食辛辣或过度饮酒，脾失健运，湿热内生，壅滞下焦；或长期久坐湿热瘀血蕴结，相火久遏不泄，精道气滞血瘀，血运不畅；或生活压力大，情志不畅致肝气郁滞；禀赋不足，肾气不足，或相火妄动，阴精暗耗，或久病及肾，阴损及阳，精关不固，膀胱失约。其病理因素为湿、热、毒，故治疗应清热解毒利湿，凉血止血，给邪以出路使热毒得清，湿邪从下而去，病因得除，以起到火灭而血自止的目的。
本中药组合物由古方“安宫牛黄丸”的衍变制成的一种中药复方制剂，中医辩证认为具有清热解毒、化痰通络、辟秽通窍、震惊安神、醒脑开窍、凉血止痛等作用，临床用于治疗温邪内陷、高热烦躁等症状。
由胆酸、猪去氧胆酸、水牛角、板蓝根、金银花、栀子、黄芩苷、珍珠母组成的中药组合物是在古代名方安宫牛黄丸的基础上开发的中药复方，即清开灵，在临床上主要用于治疗上呼吸道感染、病毒性肺炎、扁桃体炎、急慢性肝炎等疾病，此外，还被广泛应用于流行性腮腺炎、缺血性卒中、肺性脑病、心血管病及儿科疾病等诸多方面，均取得了良好的治疗效果。
处方中诸药配伍，综合多药而共济增效，其中，胆酸、猪去氧胆酸同为君药，二者为牛黄的替代品，味苦而凉，具有清热解毒，熄风定惊，豁痰开窍的功效；水牛角为臣药，味苦、咸而性寒，具有清热凉血、泻火解毒的功效；板蓝根、金银花、栀子和黄芩苷同为佐药，具有解热、抗炎及抗病毒的作用；珍珠母为使药，具有定惊安神、镇静催眠、平肝潜阳的功效。
配伍后，本发明的中药组合物具有清热解毒、利湿、凉血作用，清热解毒利湿药具有消炎解毒、控制病灶、菌毒并治、消除病源、利尿消肿的作用。而在中药组合物中加入广金钱草构成的新方，广金钱草味甘、淡，性凉，归肝、肾、膀胱经，利湿退黄、利尿通淋的药性，增效组方的利水消肿之作用。所述构成的新方，集合栀子清上、中、下三焦之火，板蓝根、金银花、栀子和黄芩苷清热解毒，抗炎抗病毒，广金钱草利湿利尿的功能，更有针对性的直达病灶，对细菌性前列腺炎具有更好的疗效。
优选地，所述治疗细菌性前列腺炎的药物的制备方法为：
S1.板蓝根180～220重量份、金银花55～65重量份和栀子22～28重量份，加或不加广金钱草15～30重量份，加水煎煮1小时，煎煮三次，合并煎液，80℃加热浓缩至相对密度为1.25，过滤得到混合提取液；
S2.水牛角22～28重量份研磨成粉，与终浓度为4mol/L的氢氧化钡溶液混合，煎煮7小时，过滤得到水牛角提取液；珍珠母45～55重量份与终浓度为4mol/L的硫酸溶液，煎煮7小时，过滤得到珍珠母提取液；合并水牛角提取液和珍珠母提取液，加热浓缩至质量相当于原料量的2倍，冷却至室温，加入体积浓度60％乙醇，混合后静置24小时；过滤，加入质量浓度20％氢氧化钠溶液，调节pH至7，60℃加热浓缩至相对密度为1.4，过滤得到提取液2；将提取液2和β环糊精25重量份，50℃、超声功率200W，超声包合50min，得到包合液；
S3.将混合提取液和包合液混合，搅拌均匀，浓缩得到浸膏；
S4.胆酸3～4重量份、猪去氧胆酸2～4重量份，用乙醇溶解，得到胆酸混合液；称取甘露醇7.5重量份，加热至熔融态，缓慢加入胆酸混合液，边加边搅拌，再放入0～5℃冷水浴中搅拌至固化，放置于50℃烘箱，干燥3小时，粉碎过80目筛，得到胆酸分散剂；
S5.黄芩苷4～6重量份，用水溶解，用氢氧化钠溶液调节pH至8，得到黄芩苷提取液；称取甘露醇5重量份，加热至熔融态，缓慢加入黄芩苷提取液，边加边搅拌，加热搅拌2小时；放置于50℃烘箱，干燥2小时，粉碎过80目筛，得到黄芩苷分散剂；
S6.将浸膏、胆酸分散剂、黄芩苷分散剂与甜味剂、香精混匀，干燥，倒入机器中制得颗粒剂。
更优选地，所述治疗细菌性前列腺炎的药物的制备方法为：
S1.板蓝根200重量份、金银花60重量份和栀子25重量份，加或不加广金钱草18重量份，加水煎煮1小时，煎煮三次，合并煎液，80℃加热浓缩至相对密度为1.25，过滤得到混合提取液；
S2.水牛角25重量份研磨成粉，与终浓度为4mol/L的氢氧化钡溶液混合，煎煮7小时，过滤得到水牛角提取液；珍珠母50重量份与终浓度为4mol/L的硫酸溶液，煎煮7小时，过滤得到珍珠母提取液；合并水牛角提取液和珍珠母提取液，加热浓缩至质量相当于原料量的2倍，冷却至室温，加入体积浓度60％乙醇，混合后静置24小时；过滤，加入质量浓度20％氢氧化钠溶液，调节pH至7，60℃加热浓缩至相对密度为1.4，过滤得到提取液2；将提取液2和β环糊精25重量份，50℃、超声功率200W，超声包合50min，得到包合液；
S3.将混合提取液和包合液混合，搅拌均匀，浓缩得到浸膏；
S4.胆酸3.25重量份、猪去氧胆酸3.75重量份，用乙醇溶解，得到胆酸混合液；称取甘露醇7.5重量份，加热至熔融态，缓慢加入胆酸混合液，边加边搅拌，再放入0～5℃冷水浴中搅拌至固化，放置于50℃烘箱，干燥3小时，粉碎过80目筛，得到胆酸分散剂；
S5.黄芩苷5重量份，用水溶解，用氢氧化钠溶液调节pH至8，得到黄芩苷提取液；称取甘露醇5重量份，加热至熔融态，缓慢加入黄芩苷提取液，边加边搅拌，加热搅拌2小时；放置于50℃烘箱，干燥2小时，粉碎过80目筛，得到黄芩苷分散剂；
S6.将浸膏、胆酸分散剂、黄芩苷分散剂与甜味剂、香精混匀，干燥，倒入机器中制得颗粒剂。
进一步地，步骤S1中，加广金钱草15～30重量份。
更进一步的，步骤S1中，加广金钱草18重量份。
与现有技术相比，本发明具有以下有益效果：
本发明研究显示，由胆酸、猪去氧胆酸、水牛角、板蓝根、金银花、栀子、黄芩苷和珍珠母组成的中药组合物，对细菌性前列腺炎具有明显的改善效果，减少病原感染，缓解炎症反应，因此，可以用于制备细菌性前列腺炎的治疗药物。
而且研究数据显示，所述中药组合物能够明显提升头孢类药物对前列腺炎的治疗作用，因此可以作为增效剂与该药物联用，用于前列腺炎的治疗。所述中药组合物还可加入广金钱草构成新方，对细菌性前列腺炎有更好的疗效，且同样可作为增效剂与头孢类药物联用，无毒安全，见效快，对临床前列腺炎的治疗具有重要的价值。
具体实施方式
下面结合说明书具体实施例对本发明作出进一步地详细阐述，所述实施例只用于解释本发明，并非用于限定本发明的范围。下述实施例中所使用的试验方法如无特殊说明，均为常规方法；所使用的材料、试剂等，如无特殊说明，为可从商业途径得到的试剂和材料。
实施例1一种中药颗粒的制备方法
1、称取板蓝根200重量份、金银花60重量份、栀子25重量份，加水煎煮1小时，煎煮三次，合并煎液，80℃加热浓缩至相对密度为1.25，过滤得到混合提取液。
2、称取水牛角25重量份，研磨成粉，加入终浓度为4mol/L的氢氧化钡溶液，煎煮7小时，过滤得到水牛角提取液；称取珍珠母50重量份，加入终浓度为4mol/L的硫酸溶液，煎煮7小时，过滤得到珍珠母提取液；将水牛角提取液和珍珠母提取液合并，加热浓缩至质量相当于原料量的2倍，冷却至室温，加入体积浓度60％乙醇，混合后静置24小时；过滤，加入质量浓度20％氢氧化钠溶液，调节pH至7，60℃加热浓缩至相对密度为1.4，过滤得到提取液2；将提取液2和β环糊精25重量份，50℃、超声功率200W，超声包合50min，得到包合液。
3、将混合提取液和包合液混合，搅拌均匀，浓缩得到浸膏。
4、称取胆酸3.25重量份、猪去氧胆酸3.75重量份，用乙醇溶解，得到胆酸混合液；称取甘露醇7.5重量份，加热至熔融态，缓慢加入胆酸混合液，边加边搅拌，再放入0～5℃冷水浴中搅拌至固化，放置于50℃烘箱，干燥3小时，粉碎过80目筛，得到胆酸分散剂。
5、称取黄芩苷5重量份，用水溶解，用氢氧化钠溶液调节pH至8，得到黄芩苷提取液；称取甘露醇5重量份，加热至熔融态，缓慢加入黄芩苷提取液，边加边搅拌，加热搅拌2小时；放置于50℃烘箱，干燥2小时，粉碎过80目筛，得到黄芩苷分散剂。
6、将浸膏、胆酸分散剂、黄芩苷分散剂与甜味剂、香精混匀，干燥，倒入机器中制得到中药颗粒。所得中药颗粒即为清开灵颗粒。
实施例2一种中药颗粒的制备方法
1、称取板蓝根200重量份、金银花60重量份、栀子25重量份、广金钱草18重量份，加水煎煮1小时，煎煮三次，合并煎液，80℃加热浓缩至相对密度为1.25，过滤得到混合提取液。
2、称取水牛角25重量份，研磨成粉，加入终浓度为4mol/L的氢氧化钡溶液，煎煮7小时，过滤得到水牛角提取液；称取珍珠母50重量份，加入终浓度为4mol/L的硫酸溶液，煎煮7小时，过滤得到珍珠母提取液；将水牛角提取液和珍珠母提取液合并，加热浓缩至质量相当于原料量的2倍，冷却至室温，加入体积浓度60％乙醇，混合后静置24小时；过滤，加入质量浓度20％氢氧化钠溶液，调节pH至7，60℃加热浓缩至相对密度为1.4，过滤得到提取液2；将提取液2和β环糊精25重量份，50℃、超声功率200W，超声包合50min，得到包合液。
3、将混合提取液和包合液混合，搅拌均匀，浓缩得到浸膏。
4、称取胆酸3.25重量份、猪去氧胆酸3.75重量份，用乙醇溶解，得到胆酸混合液；称取甘露醇7.5重量份，加热至熔融态，缓慢加入胆酸混合液，边加边搅拌，再放入0～5℃冷水浴中搅拌至固化，放置于50℃烘箱，干燥3小时，粉碎过80目筛，得到胆酸分散剂。
5、称取黄芩苷5重量份，用水溶解，用氢氧化钠溶液调节pH至8，得到黄芩苷提取液；称取甘露醇5重量份，加热至熔融态，缓慢加入黄芩苷提取液，边加边搅拌，加热搅拌2小时；放置于50℃烘箱，干燥2小时，粉碎过80目筛，得到黄芩苷分散剂。
6、将浸膏、胆酸分散剂、黄芩苷分散剂与甜味剂、香精混匀，干燥，倒入机器中制得到中药颗粒。所得中药颗粒即为添加广金钱草的新方清开灵颗粒。实施例3中药颗粒的体外抑菌效果
一、实验方法
1、用无菌接种环将金黄色葡萄球菌、表皮葡萄球菌、大肠杆菌、铜绿假单胞菌分别接种于营养琼脂培养基上，37℃恒温培养箱培养24h。分别挑取4种菌株的单个菌落用无菌水稀释，制得浓度约为2×108CFU/mL的菌悬液。
2、称取广金钱草200重量份，加水煎煮1小时，煎煮三次，合并煎液，80℃加热浓缩成浸膏，倒入机器中制得到广金钱草颗粒。
3、采用二倍稀释法，将实施例1所得的清开灵颗粒配制成浓度梯度为1g/mL、0.5g/mL、0.25g/mL、0.125g/mL、0.0625g/mL、0.0313g/mL、0.0156g/mL、0.0078g/mL、0.0039g/mL的溶液，记为实施例1梯度液。采用同样的方法，将实施例2所得的新方清开灵颗粒配制成相同浓度梯度的溶液，记为实施例2梯度液；将广金钱草颗粒配制成相同浓度梯度的溶液，记为广金钱草梯度液。
4、向实施例1梯度液、实施例2梯度液和广金钱草梯度液分别加入20μL步骤(1)所得菌悬液，37℃恒温培养箱培养24h。观察各梯度液中菌株的生长情况，测定最低抑菌浓度(MIC)。
二、实验结果
表1、中药颗粒的最低抑菌浓度(MIC)
如表1所示，按照实施例1和实施例2所述方法制得的中药颗粒都对金黄色葡萄球菌、表皮葡萄球菌、大肠杆菌、铜绿假单胞菌有一定的抑制效果，其中实施例2所得的新方清开灵颗粒对金黄色葡萄球菌和铜绿假单胞菌的最低抑菌浓度更小，有更好的抑菌效果，具有协同增效。
实施例4中药颗粒治疗细菌性前列腺炎的效果
一、实验方法
1、小鼠模型构建
将78只雄性成年SD大鼠(体重约350g)随机分为13组，每组6只，记为A～M组。
所有大鼠用乙醚麻醉，消毒下腹部，用手术剪剪开腹壁，使膀胱背侧的前列腺暴露，其中A组大鼠直接缝合肌肉和皮肤，用碘伏消毒缝合处；B～G组大鼠的前列腺两背侧叶注入0.2×1010个/mL金黄色葡萄球菌，再进行缝合，消毒。术后保持大鼠自由采食活动。
术后第10天开始，使用使用头孢克肟颗粒、头孢拉定胶囊、头孢地尼颗粒、实施例1制得的清开灵颗粒和实施例2制得的新方清开灵颗粒，每天按照如表2所示的用药方案对A～M组大鼠进行灌喂，溶剂为饮用水，持续灌胃14天。
表2、灌喂大鼠的用药方案
A组作为阴性对照组；B组作为阳性对照组；C～M组作为用药处理组，其中C～E组为头孢类药物处理组；F～G组为中药颗粒处理组；H～M组为中药颗粒与头孢类药物联用处理组。
2、采样
灌胃14天后，将全部大鼠称重后处死，记录大鼠的体重。收集所有大鼠的前列腺和血清用于后续检测。
3、前列腺的组织学观察
将灌胃第14天采集到的前列腺称重，根据公式：前列腺指数＝前列腺湿重(mg)÷体重(g)，计算各组大鼠的前列腺指数。并在解剖镜下进行观察，记录各组前列腺组织的粘连及化脓的情况。
4、细菌培养
每只大鼠采集到的前列腺，取一部分放入组织匀浆器中，加入无菌的生理盐水进行研磨，制成质量浓度10％的组织匀浆液。
取0.1mL组织匀浆液，置于琼脂固体培养基中，37℃培养过夜，统计各组的大鼠前列腺组织细菌的总数即ΣCFU，根据公式：抑菌率＝[(阳性对照组ΣCFU－用药处理组ΣCFU)/阳性对照组ΣCFU]×100％，计算各组的抑菌率。
5、炎症因子检测
使用ELISA试剂盒(ebioscience，美国)检测大鼠血清及前列腺中肿瘤坏死因子-α(TNF-α)及白细胞介素-8(IL-8)的含量。
二、实验结果
表3、前列腺指数的统计情况
如表3所示，实施例1制得的清开灵颗粒和实施例2制得的新方清开灵颗粒治疗细菌性前列腺炎大鼠，均可降低前列腺指数。与单独使用头孢类药物治疗相比，头孢类药物与实施例1的清开灵颗粒联用、头孢类药物与实施例2的新方清开灵颗粒联用的情况下，患病大鼠的前列腺指数下降更为显著。
表4、前列腺的组织学观察情况
如表4所示，实施例1制得的清开灵颗粒和实施例2制得的新方清开灵颗粒治疗细菌性前列腺炎大鼠，均可减少前列腺组织粘连并缓解炎症反应。与单独使用头孢类药物治疗相比，头孢类药物与实施例1的清开灵颗粒联用、头孢类药物与实施例2的新方清开灵颗粒联用的情况下，患病大鼠的粘连和化脓的改善效果更佳。
表5、抑菌率的统计情况
如表5所示，实施例2所得的新方清开灵颗粒与头孢类药物在大鼠体内的抑菌效果相当。头孢类药物与实施例1的清开灵颗粒联用、头孢类药物与实施例2的新方清开灵颗粒联用治疗细菌性前列腺炎大鼠的抑菌效果明显优于单独使用头孢类药物治疗。
表6、血清炎症因子的含量
如表6所示，实施例1制得的清开灵颗粒和实施例2制得的新方清开灵颗粒均可有效降低细菌性前列腺炎大鼠血清中炎症因子的含量，缓解炎症反应，实施例1制得的清开灵颗粒和实施例2制得的新方清开灵颗粒与头孢类药物联用后疗效更佳。
综上，本发明提供的中药颗粒能够有效抑制病原菌生长、减少感染、缓解炎症反应，对细菌性前列腺炎具有显著疗效。
最后所应当说明的是，以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制，对于本领域的普通技术人员来说，在上述说明及思路的基础上还可以做出其它不同形式的变化或变动，这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明权利要求的保护范围之内。
Claims (10)
1.一种中药组合物在制备治疗细菌性前列腺炎的药物中的应用，其特征在于，所述中药组合物由胆酸3～4重量份、猪去氧胆酸2～4重量份、水牛角22～28重量份、板蓝根180～220重量份、金银花55～65重量份、栀子22～28重量份、黄芩苷4～6重量份、珍珠母45～55重量份和广金钱草15～30重量份制成。
2.一种联用组合药物在制备治疗细菌性前列腺炎的药物中的应用，其特征在于，所述联用组合药物含有中药组合物和头孢类药物，所述中药组合物由胆酸3～4重量份、猪去氧胆酸2～4重量份、水牛角22～28重量份、板蓝根180～220重量份、金银花55～65重量份、栀子22～28重量份、黄芩苷4～6重量份、珍珠母45～55重量份和广金钱草15～30重量份制成。
3.根据权利要求1～2任一所述的应用，其特征在于，所述中药组合物由胆酸3.25重量份、猪去氧胆酸3.75重量份、水牛角25重量份、板蓝根200重量份、金银花60重量份、栀子25重量份、黄芩苷5重量份、珍珠母50重量份和广金钱草18重量份制成。
4.根据权利要求1～2任一所述的应用，其特征在于，所述细菌性前列腺炎为急性细菌性前列腺炎或慢性细菌性前列腺炎。
5.根据权利要求1～2任一所述的应用，其特征在于，所述细菌性前列腺炎的病原菌含有大肠杆菌、表皮葡萄球菌、金黄色葡萄球菌和/或铜绿假单胞菌中的一种或几种。
6.一种治疗细菌性前列腺炎的药物，其特征在于，由胆酸3～4重量份、猪去氧胆酸2～4重量份、水牛角22～28重量份、板蓝根180～220重量份、金银花55～65重量份、栀子22～28重量份、黄芩苷4～6重量份、珍珠母45～55重量份和广金钱草15～30重量份制成。
7.根据权利要求6所述的药物，其特征在于，由胆酸3.25重量份、猪去氧胆酸3.75重量份、水牛角25重量份、板蓝根200重量份、金银花60重量份、栀子25重量份、黄芩苷5重量份、珍珠母50重量份和广金钱草18重量份制成。
8.一种治疗细菌性前列腺炎的联用组合药物，其特征在于，包含权利要求6～7任一所述的药物和头孢类药物。
9.根据权利要求8所述的联用组合药物，其特征在于，所述头孢类药物为头孢克肟、头孢拉定和/或头孢地尼中的一种或几种。
10.根据权利要求8所述的联用组合药物，所述头孢类药物为头孢克肟颗粒、头孢拉定胶囊和头孢地尼颗粒中的一种或几种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211275190.9A CN115569165B (zh) | 2022-10-18 | 2022-10-18 | 中药组合物在制备治疗细菌性前列腺炎的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211275190.9A CN115569165B (zh) | 2022-10-18 | 2022-10-18 | 中药组合物在制备治疗细菌性前列腺炎的药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115569165A CN115569165A (zh) | 2023-01-06 |
| CN115569165B true CN115569165B (zh) | 2023-11-03 |
Family
ID=84584606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211275190.9A Active CN115569165B (zh) | 2022-10-18 | 2022-10-18 | 中药组合物在制备治疗细菌性前列腺炎的药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115569165B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209302A (zh) * | 2006-12-29 | 2008-07-02 | 贵州益佰制药股份有限公司 | 一种清热解毒的中药制剂及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878470B (zh) * | 2016-06-19 | 2019-07-05 | 神威药业集团有限公司 | 一种清开灵药物组合物 |
-
2022
- 2022-10-18 CN CN202211275190.9A patent/CN115569165B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209302A (zh) * | 2006-12-29 | 2008-07-02 | 贵州益佰制药股份有限公司 | 一种清热解毒的中药制剂及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| 张桂芝，陈豪君.清开灵在中医内科急症的临床应用.实用医学杂志.1994,第10卷(第02期),153. * |
| 纪永军 ; 刘金山 ; .清开灵注射液不良反应22例分析.中国误诊学杂志.2009,第9卷(第34期),8511. * |
| 范文昌 ; 梅全喜 ; 赖海标 ; .广金钱草的药理作用和临床应用研究进展.中国药房.2010,(第31期),2962. * |
| 魏瑜 ; .清开灵胶囊抑菌作用的实验研究.中国民族民间医药.2014,(第24期),8. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115569165A (zh) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853287B (zh) | 一种抗人乳头瘤病毒及抗妇科炎症的药物组合物、凝胶制剂及应用 | |
| CN112316017A (zh) | 一种妇科抑菌凝胶及其制备方法 | |
| WO2018188525A1 (zh) | 一种改善机体内循环，延缓衰老的组合物及其用途 | |
| CN105709081B (zh) | 治疗鸡传染性鼻炎的药物组合物，其应用及饲料 | |
| CN115569165B (zh) | 中药组合物在制备治疗细菌性前列腺炎的药物中的应用 | |
| CN101391065B (zh) | 一种用于治疗急慢性盆腔炎的木鳖子花椒汤 | |
| CN104547186A (zh) | 用于预防、治疗禽霍乱的复方发酵型中药及其制备方法 | |
| CN1686492A (zh) | 一种抗菌消炎胶囊及其制备方法 | |
| CN102793869B (zh) | 一种用于防治猪病毒性疾病的中药组合物及其制备方法 | |
| CN115531454B (zh) | 组合物作为治疗阴道炎的增效剂在制备药物中的应用 | |
| CN105412321A (zh) | 一种制备治疗前列腺炎的中药组合物颗粒剂的方法 | |
| CN113599432B (zh) | 一种预防草鱼细菌性肠炎的中药及其制备方法 | |
| CN114569680B (zh) | 一种治疗热淋的组合物及其制备方法和应用 | |
| CN115607614B (zh) | 一种治疗畜禽大肠杆菌病的中药组合物及其制备方法 | |
| CN108339026A (zh) | 一种中兽药复方注射液及其制备方法与新用途 | |
| CN113082140B (zh) | 一种治疗奶牛急性乳房炎的中药复合物及其制备方法 | |
| CN106421220A (zh) | 一种海洋生物护伤喷膜剂的制备方法 | |
| CN112618600B (zh) | 一种用于治疗犊牛胃肠道疾病药物的藏药复方及其制备方法 | |
| CN105641329A (zh) | 一种用于阑尾炎术后护理的中药组合物 | |
| CN105920463A (zh) | 一种治疗水貂绿脓杆菌性肺炎的膏剂及其制备方法 | |
| CN117752736A (zh) | 一种防治鸡波氏杆菌的中药组合物及其制备方法和应用 | |
| CN115025182A (zh) | 一种治疗呼吸道病毒感染的中药制剂 | |
| CN117122665A (zh) | 雏鸡开口药 | |
| CN110179866A (zh) | 一种中医内科治疗腹泻的中药药膏及其制备方法 | |
| CN117482100A (zh) | 一种裸花紫珠提取物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |